| Literature DB >> 26732684 |
José das Neves1, João Pedro Martins2, Bruno Sarmento3.
Abstract
Microbicides are being developed in order to prevent sexual transmission of HIV. Dapivirine, a non-nucleoside reverse transcriptase inhibitor, is one of the leading drug candidates in the field, currently being tested in various dosage forms, namely vaginal rings, gels, and films. In particular, a ring allowing sustained drug release for 1month is in an advanced stage of clinical testing. Two parallel phase III clinical trials are underway in sub-Saharan Africa and results are expected to be released in early 2016. This article overviews the development of dapivirine and its multiple products as potential microbicides, with particular emphasis being placed on clinical evaluation. Also, critical aspects regarding regulatory approval, manufacturing, distribution, and access are discussed.Entities:
Keywords: ASPIRE; Dapivirine (PubChem CID: 214347); Darunavir (PubChem CID: 213039); Maraviroc (PubChem CID: 3002977); Pre-exposure prophylaxis; Tenofovir (PubChem CID: 464205); The Ring Study; Vaginal film; Vaginal gel; Vaginal ring
Mesh：
Substances：
Year: 2015 PMID： 26732684 DOI： 10.1016/j.addr.2015.12.015
Source DB: PubMed Journal: Adv Drug Deliv Rev ISSN： 0169-409X Impact factor: 15.470